4.6 Article

Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers

期刊

BRITISH JOURNAL OF HAEMATOLOGY
卷 200, 期 1, 页码 64-69

出版社

WILEY
DOI: 10.1111/bjh.18469

关键词

AML; CAR; cell therapy; cytokine-induced killer lymphocytes; HSC transplantation

向作者/读者索取更多资源

This study explored the feasibility, anti-leukaemic activity, and alloreactive risk of genetically redirected CIK (fcCAR.CIK) generated from full-donor chimaeric patients. The results showed that fcCAR.CIK exhibited intense preclinical anti-leukaemic activity without enhancing the risk of graft-versus-host disease, supporting the potential use of fcCAR.CIK as an alternative to conventional donor lymphocyte infusion following haematopoietic cell transplantation.
Cytokine-induced killer lymphocytes (CIK) are a promising alternative to conventional donor lymphocyte infusion (DLI), following allogeneic haematopoietic cell transplantation (HCT), due to their intrinsic anti-tumour activity and reduced risk of graft-versus-host disease (GVHD). We explored the feasibility, anti-leukaemic activity and alloreactive risk of CIK generated from full-donor chimaeric (fc) patients and genetically redirected by a chimeric antigen receptor (CAR) (fcCAR.CIK) against the leukaemic target CD44v6. fcCAR.CIK were successfully ex-vivo expanded from leukaemic patients in complete remission after HCT confirming their intense preclinical anti-leukaemic activity without enhancing the alloreactivity across human leukocyte antigen (HLA) barriers. Our study provides translational bases to support clinical studies with fcCAR.CIK, a sort of biological bridge between the autologous and allogeneic sources, as alternative DLI following HCT.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据